Venomics AI
Venomics AI is a Bengaluru-based biotech spun out of the Indian Institute of Science that turns venom-derived peptides into drug candidates.
Position in SVTRnew
Snapshot 2026-11-06- Startup SignalsRankedof 2,346
- Life SciencesRankedof 250
- AI for ScienceRankedof 116
- Drug DiscoveryRankedof 72
About
Venomics AI is a Bengaluru-based biotech spun out of the Indian Institute of Science that turns venom-derived peptides into drug candidates. Its Venom Atlas platform combines a large toxin-peptide dataset with genomics, high-throughput electrophysiology, AI modeling and protein engineering, targeting pain, metabolic disease, antimicrobial resistance, oncology, senescence and bioinsecticides.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Founders / team· 2
Funding history
- 2026-11-05Pre-Seed$3M
Investors · Speciale Invest, South Park Commons, Operators StudioSource · inc42.com ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Venomics AI
Venomics AI is a Bengaluru-based biotech spun out of the Indian Institute of Science that turns venom-derived peptides into drug candidates.
Pre-Seed · $3M · 2026-11
$3M
United States
BusinessLatest roundTotal raisedDate- Escalante
Drug discovery and diagnostics platform combining AI with single-molecule proteomics
$7M
$7M - Pepper Bio
Analyzes multi-layer biological data (including DNA, RNA, proteomic and phosphoproteomic data) to discover new drugs
Seed · $7M · 2023-12
$7M - Enveda Biosciences
Discovers naturally derived drugs from plants and microbes using its in-house AI foundation model PRISM; three oral drug candidates have entered clini…
Series D+ · $845M · 2026-09 · Valuation $2.0B
$845MValuation $2.0B
China
BusinessLatest roundTotal raisedDate- Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design…
Series D+ · $210M · 2025-03
$210M - Anew Labs
AI-driven drug discovery and new drug development platform
Undisclosed · $290M · 2026-09 · Valuation $1.5B
$290MValuation $1.5B - NeuShen Therapeutics
Novel drugs for CNS psychiatric and neurological disorders…
Series B · 2026-09
—
Europe
BusinessLatest roundTotal raisedDate- Cyclana Bio
Tissue-level drug discovery model for treating endometriosis
Pre-Seed · $7M · 2025-10
$7M - Sightera Biosciences
AI-native drug discovery: patient-derived disease models and generative AI to design small-molecule cancer/fibrosis therapies
Pre-Seed · $3M · 2026-07
$3M - Bio Protocol
Funds and accelerates drug discovery through decentralized research agents
Seed · $7M · 2025-09
$7M
Other / unspecified
BusinessLatest roundTotal raisedDate- Elixion Biotech
Cancer drug target discovery platform driven by quantum physics, causal biology, multi-omics and AI
— - Astellas Pharma
Research, manufacturing and sale of prescription drugs in oncology, ophthalmology, urology, immunology and women's health.
— - Miles Wang 新公司
Develops AI models for drug discovery
—
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Khosla Ventures
21 Life Sciences deals in the last 24 months · 7 at a nearby stage · 1 in South Asia
Request intro →Blume Ventures
3 Life Sciences deals in the last 24 months · 2 at a nearby stage · 1 in South Asia
Request intro →Andreessen Horowitz
22 Life Sciences deals in the last 24 months · 11 at a nearby stage
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.